IBCSG 50-14 OLYMPIA

  • A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.

    • Study Chair
      Dr. Lorenzo Gianni, Rimini, Italy

      Trial Coordinators
      Poonam Jani, Dorene Polizzi

      Monitoring
      ETOP IBCSG Partners Foundation
      Coordinating Center, Bern, Switzerland
      Phone: +41 31 511 94 00
      Fax: +41 31 511 94 01
      Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

      IBCSG Data Management Center/FSTRF
      4033 Maple Road
      Amherst, New York 14226 USA
      Phone: +1 716 834 0900
      Fax: +1 716 833 3990
      Email:       This email address is being protected from spambots. You need JavaScript enabled to view it.



      Date of Activation
      July 25, 2014

      Targeted Accrual
      1320

    ETOP IBCSG Partners Foundation
    Effingerstrasse 33
    3008 Bern, Switzerland

    Contact
    Phone: +41 31 511 94 00
    E-mail: contact@etop.ibcsg.org

    Member Login